アトピー性皮膚炎(AD)の疫学予測

◆英語タイトル:Atopic Dermatitis (AD) -Epidemiology Forecast
◆商品コード:DELV803003
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2018年3月
◆ページ数:50
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2営業日以内)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,250 ⇒換算¥357,500見積依頼/購入/質問フォーム
Site Price(同一事業所内共有可)USD6,500 ⇒換算¥715,000見積依頼/購入/質問フォーム
Enterprise Price(同一法人内共有可)USD9,750 ⇒換算¥1,072,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

DelveInsight’s ‘Atopic Dermatitis – Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Atopic Dermatitis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Atopic Dermatitis Epidemiology
The Atopic Dermatitis (AD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Atopic Dermatitis are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Atopic Dermatitis Epidemiology Segmentation
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology, scenario of Atopic Dermatitis (AD) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The disease epidemiology covered in the report is segmented by prevalent population of Atopic Dermatitis, Severity [Children & Adults], Pruritus burden, Pruritus Severity [Moderate to Severe], Uncontrolled Atopic Dermatitis [Children & Adults] in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to DelveInsight, the prevalent population of Atopic Dermatitis was estimated to be 40.78 Million [7MM] in 2016 and, is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. United States accounts for the highest AD Cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Adults are largely affected with the atopic dermatitis Among EU5, France has been reported to have the highest prevalent population of atopic dermatitis.

Report Scope
• The report covers detailed overview of Atopic Dermatitis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The report provides the insight about the historical and forecasted patient pool of Atopic Dermatitis in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Report assesses the disease risk and burden and highlights the unmet needs of the disease
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the segmentation of the disease epidemiology by Severity [Children & Adults], Pruritus burden, Pruritus Severity [Moderate to Severe], Uncontrolled Atopic Dermatitis [Children & Adults] in 7MM

Key strengths
• 10 Year Forecast of Atopic Dermatitis epidemiology
• 7MM Coverage
• Total Prevalent Cases of Atopic Dermatitis
• Prevalent Cases according to segmentation: by Severity [Children & Adults], Pruritus burden, Pruritus Severity [Moderate to Severe], Uncontrolled Atopic Dermatitis [Children & Adults]

Key assessments
• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

【レポートの目次】

1. Report Introduction
2. Atopic Dermatitis Epidemiology Overview at a Glance
2.1. Prevalent Population of Atopic Dermatitis in 2017
2.2. Prevalent Populationof Atopic Dermatitis in 2027
3. Disease Background and Overview
3.1. Etiology
3.2. Risk Factors
3.3. Pathophysiology
3.4. Atopic Dermatitis
3.4.1. Pruritus Associated with Atopic Dermatitis
3.4.2. Diagnosis
4. Epidemiology and Patient Population
4.1. Disease Definition
4.2. Population and Forecast Parameters
4.3. Population Methods
4.3.1. Total prevalent cases in US
4.3.2. EU5
4.3.3. Japan
4.4. Prevalent Population of Atopic Dermatitis in 7MM
4.5. Prevalent Population of Atopic Dermatitis in United States
4.6. Prevalent Population of Atopic Dermatitis in Germany
4.7. Prevalent Population of Atopic Dermatitis in France
4.8. Prevalent Population of Atopic Dermatitis in Italy
4.9. Prevalent Population of Atopic Dermatitis in Spain
4.10. Prevalent Population of Atopic Dermatitis in United Kingdom
4.11. Prevalent Population of Atopic Dermatitis in Japan
4.12. Prevalent Population of Atopic Dermatitis by Severity in 7MM
4.13. Prevalent Population of Atopic Dermatitis by Severity in Children in 7MM
4.14. Prevalent Population of Atopic Dermatitis by Severity in Adults in 7MM
4.15. Prevalent Cases of Atopic Dermatitis by Pruritus Burden in 7MM
4.16. Prevalent Cases of Atopic Dermatitis by Pruritus Severity in Moderate to Severe Cases
4.17. Prevalent Cases with Uncontrolled Atopic Dermatitis in 7MM
4.18. Prevalent Cases with Uncontrolled Atopic Dermatitis in Children and Adults in 7MM
5. Treatment Practices
6. Treatment Algorithm
6.1. Treatment Goals
6.2. Treatment Guidelines by American Academy of Dermatology
6.3. Japanese Guidelines for Atopic Dermatitis 2017
6.4. Guidelines on the Treatment of Atopic Eczema (Atopic Dermatitis): European Dermatology Forum
7. Current Unmet Need
8. Appendix
9. Report Methodology
9.1. Source Used
10. DelevInsight Capabilities
11. Disclaimer
12. About DelveInsight

Table 1: Targets focused by companies
Table 2: Concept of Atopic Dermatitis by Wise and Sulzberger
Table 3: Hanifin and Rajka Diagnostic Criteria
Table 4: United Kingdom Working Party diagnostic criteria
Table 5: American Academy of Dermatology Diagnostic Criteria
Table 6: Japanese Dermatological Association Diagnostic Criteria
Table 7: Total Prevalent Population of Atopic Dermatitis in 7 MM (2016-2027)
Table 8: Prevalent Population of Atopic Dermatitis in United States (2016-2027)
Table 9: Prevalent Population of Atopic Dermatitis in Germany (2016-2027)
Table 10: Prevalent Population of Atopic Dermatitis in France (2016-2027)
Table 11: Prevalent Population of Atopic Dermatitis in Italy (2016-2027)
Table 12: Prevalent Population of Atopic Dermatitis in Spain (2016-2027)
Table 13: Prevalent Population of Atopic Dermatitis in United Kingdom (2016-2027)
Table 14: Prevalent Population of Atopic Dermatitis in Japan (2016-2027)
Table 15: Prevalent Cases of Atopic Dermatitis by Severity in 7MM
Table 16: Prevalent Cases of Atopic Dermatitis by Severity in Children in 7MM
Table 17: Prevalent Cases of Atopic Dermatitis by Severity in Adult in 7MM
Table 18: Total Prevalent Population of Atopic Dermatitis by Pruritus Burden in 7 MM (2016-2027)
Table 19: Prevalent Cases of Atopic Dermatitis by Pruritus Severity in Moderate to Severe Cases in 7MM (2016-2027)
Table 20: Total Prevalent Population with Uncontrolled Atopic Dermatitis in 7 MM (2016-2027)
Table 21:Total Prevalent Population with Uncontrolled Atopic Dermatitis in Children and Adults in 7 MM (2016-2027)
Table 22: Topical corticosteroids used for the treatment of Atopic Dermatitis
Table 23: Topical Calcineurin Inhibitors (TCIs)
Table 24: Topical Phosphodiesterase Type-4 (PDE4) inhibitors
Table 25: Oral Corticosteroids
Table 26: Biologic medications
Table 27: Non-approved systemic immunomodulating agents
Table 28: Reasons for noncompliance with medication


Figure 1: Risk Factors for Atopic Dermatitis
Figure 2: Summary of pathogenic mechanisms in acute and chronic atopic dermatitis (AD)
Figure 3: Pathophysiology of Pruritus in Atopic Dermatitis
Figure 4: Mediators involved in Pathophysiology of Pruritus in Atopic Dermatitis
Figure 5: Total Prevalent Population of Atopic Dermatitis in 7 MM (2016-2027)
Figure 6: Total Prevalent Population of Atopic Dermatitis in United States (2016-2027)
Figure 7: Total Prevalent Population of Atopic Dermatitis in Germany (2016-2027)
Figure 8: Total Prevalent Population of Atopic Dermatitis in France (2016-2027)
Figure 9: Total Prevalent Population of Atopic Dermatitis in Italy (2016-2027)
Figure 10: Total Prevalent Population of Atopic Dermatitis in Spain (2016-2027)
Figure 11: Total Prevalent Population of Atopic Dermatitis in the United Kingdom (2016-2027)
Figure 12: Total Prevalent Population of Atopic Dermatitis in Japan (2016-2027)
Figure 13: Total Prevalent Population of Atopic Dermatitis by Severity in 7 MM (2016-2027)
Figure 14: Total Prevalent Population of Atopic Dermatitis by Severity in Children in 7 MM (2016-2027)
Figure 15: Total Prevalent Population of Atopic Dermatitis by Severity in Adult in 7 MM (2016-2027)
Figure 16: Total Prevalent Population of Atopic Dermatitis by Pruritus Burden in 7 MM (2016-2027)
Figure 17: Prevalent Cases of Atopic Dermatitis by Pruritus Severity in Moderate to Severe Cases in 7MM (2016-2027)
Figure 18: Total Prevalent Population with Uncontrolled Atopic Dermatitis in 7 MM (2016-2027)
Figure 19:Total Prevalent Population with Uncontrolled Atopic Dermatitis in Children and Adults in 7 MM (2016-2027)
Figure 20: General Treatment for Atopic Dermatitis
Figure 21: First Line and second line treatment of Atopic Dermatitis
Figure 22: Current stepped treatment options for Atopic dermatitis
Figure 23: Current Unmet Need for Atopic Dermatitis


【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ アトピー性皮膚炎(AD)の疫学予測(Atopic Dermatitis (AD) -Epidemiology Forecast)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆